Novartis Pharma (Canadian and European rights for Emselex/Enablex) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Novartis Pharma (Canadian and European rights for Emselex/Enablex) General Information
Description
Canadian and European rights for a prescription medicine product. The regional rights comprise of rights to manufacture, market and sell the branded prescription medicine product Emselex and Enablex (darifenacin) extended release tablets. Darifenacin is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Contact Information
Corporate Office
- Canada
Corporate Office
- Canada
Novartis Pharma (Canadian and European rights for Emselex/Enablex) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Novartis Pharma (Canadian and European rights for Emselex/Enablex) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Novartis Pharma (Canadian and European rights for Emselex/Enablex) FAQs
-
Where is Novartis Pharma (Canadian and European rights for Emselex/Enablex) headquartered?
Novartis Pharma (Canadian and European rights for Emselex/Enablex) is headquartered in Canada.
-
What industry is Novartis Pharma (Canadian and European rights for Emselex/Enablex) in?
Novartis Pharma (Canadian and European rights for Emselex/Enablex)’s primary industry is Buildings and Property.
-
Is Novartis Pharma (Canadian and European rights for Emselex/Enablex) a private or public company?
Novartis Pharma (Canadian and European rights for Emselex/Enablex) is a Private company.
-
What is Novartis Pharma (Canadian and European rights for Emselex/Enablex)’s current revenue?
The current revenue for Novartis Pharma (Canadian and European rights for Emselex/Enablex) is .
-
Who are Novartis Pharma (Canadian and European rights for Emselex/Enablex)’s investors?
Novartis Pharma has invested in Novartis Pharma (Canadian and European rights for Emselex/Enablex).
-
When was Novartis Pharma (Canadian and European rights for Emselex/Enablex) acquired?
Novartis Pharma (Canadian and European rights for Emselex/Enablex) was acquired on 11-Jul-2012.
-
Who acquired Novartis Pharma (Canadian and European rights for Emselex/Enablex)?
Novartis Pharma (Canadian and European rights for Emselex/Enablex) was acquired by Merus Labs International.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process